Peripheral arterial disease (PAD) affects over 230 million people globally, and its most severe manifestation \u2014 critical limb ischemia (CLI) \u2014 carries a prognosis that surgeons dread: without revascularization, roughly one in four CLI patients lose a limb within a year. The tragedy is that up to 40% of CLI patients have disease anatomy that makes conventional bypass or endovascular revascularization technically impossible. For these patients, mesenchymal stromal cell therapy is no longer an academic curiosity \u2014 it is an active area of translational urgency, and 2026 has delivered substantial mechanistic and clinical progress that pushes the field well beyond earlier proof-of-concept work.<\/p>\n
<\/p>\n
Standard MSC transplantation into ischemic limb muscle faces a fundamental problem: the ROS-rich microenvironment of CLI kills transplanted cells before they can secrete enough paracrine factors to stimulate vascular regrowth. Clinically, this explains why cell therapy trials in CLI have shown inconsistent efficacy despite consistent safety \u2014 the cells simply do not survive long enough.<\/p>\n
A 2026 study in Molecular Therapy<\/em> by Shin EJ et al. confronted this obstacle at its genetic root using CRISPR-Cas9. The team targeted Kelch-like ECH-associated protein 1 (KEAP1) \u2014 the cytoplasmic repressor that normally keeps the NRF2 antioxidant transcription factor in check. Knockout of KEAP1 in human bone marrow-derived MSCs constitutively activated the NRF2 pathway, reprogramming the cells’ entire redox regulatory network. Edited MSCs showed reduced intracellular ROS accumulation, upregulated HGF, VEGF, and IL-6 paracrine gene expression, and markedly enhanced survival under hypoxia-mimetic conditions in vitro.<\/p>\n In a murine CLTI model, KEAP1-edited MSCs delivered intramuscularly achieved significantly better engraftment than unmodified MSCs, with superior tissue perfusion (laser Doppler imaging) and arteriogenesis (CD31+ vessel density). The approach uses non-viral CRISPR editing \u2014 no integration cassette \u2014 which makes it potentially amenable to clinical-grade manufacturing. More broadly, this strategy is applicable to any MSC application where ischemia\/reperfusion damages transplanted cells: myocardial infarction, stroke, and diabetic complications are all candidate indications for NRF2-primed MSCs.<\/p>\n Diabetic CLI patients represent the single largest subgroup in limb salvage clinics, yet they are also the patients whose own bone marrow produces the lowest quality MSCs. Hyperglycemia impairs MSC proliferative capacity, paracrine output, and immunomodulatory function \u2014 the exact properties that make MSCs therapeutic. A February 2026 paper in Bioengineering & Translational Medicine<\/em> (Basu R et al.) addressed this population mismatch by generating MSCs from human induced pluripotent stem cells (hiPSC-MSCs), which are not affected by the donor’s metabolic status.<\/p>\n In a streptozotocin-induced diabetic CLTI model, hiPSC-MSCs injected intramuscularly produced multi-lineage improvements: muscle regeneration markers embryonic myosin heavy chain 3 (p < 0.01) and myoblast determination protein 1 (p = 0.03) were upregulated, VEGF-A expression increased at 7 days (p = 0.04), and the oxidative stress marker p47phox decreased at 30 days (p = 0.02). On the immunological axis, Foxp3 (Treg marker, p = 0.01 at 7 days) and CD206 (M2 macrophage marker, p = 0.04 at 7 days and p = 0.02 at 30 days) were both significantly elevated, suggesting that hiPSC-MSCs drive macrophage polarization from pro-inflammatory M1 to reparative M2 \u2014 a cascade that orchestrates both angiogenesis and muscle fiber regeneration.<\/p>\n hiPSC-MSCs have a key manufacturing advantage: they can be expanded from a single master cell bank under cGMP conditions, with lot-to-lot consistency that autologous harvests cannot match. For the CLI population, where many patients are elderly, diabetic, or renally impaired, the ability to manufacture a standardized product without harvesting bone marrow or adipose tissue under general anesthesia is a practical advance.<\/p>\n One of the most innovative 2026 contributions comes from Kim DY et al. in npj Regenerative Medicine<\/em> (January 2026), who tested whether combining two adipose-derived progenitor populations \u2014 vascular multipotent stem cells (VMSCs) and adipose-derived stem cells (ADSCs) \u2014 would achieve superior vascular repair through complementary mechanisms.<\/p>\n Phenotypic characterization revealed that VMSCs express endothelial markers (CD31, VE-cadherin, CD141) and form capillary-like tubes in Matrigel, while ADSCs express perivascular markers (alpha-SMA, Transgelin) and function as mural support cells. Co-culture of VMSCs with ADSCs produced branched, stable tubular networks \u2014 something neither population could achieve alone. In a murine CLI model, combined intramuscular VMSC + ADSC transplantation significantly reduced limb necrosis and promoted both arteriogenesis (large-vessel formation) and angiogenesis (capillary sprouting). Histologically, transplanted cells physically integrated into host vascular structures, forming hybrid human-mouse vessels.<\/p>\n This finding \u2014 that transplanted cells directly participate in vessel wall construction, not just paracrine signaling \u2014 is mechanistically significant. It suggests that a two-component cell product mimicking the vessel wall architecture (endothelium + pericyte) may produce more durable vascular repair than any single-cell therapy. The approach is autologous (both populations derived from the same lipoaspirate), simplifying regulatory pathfinding.<\/p>\n For clinicians and regulators seeking a cell-free, defined product, hUCB-MSC-derived exosomes represent a compelling alternative. A 2026 study in Current Stem Cell Research and Therapy<\/em> (Du L et al.) demonstrated that exosomal miR-21-5p is the key cargo driving endothelial tip cell activation: exosome treatment enhanced tip cell proliferation (EdU staining), migration (Transwell), and viability (CCK-8), while reducing apoptosis (flow cytometry). The mechanism was mapped to miR-21-5p-mediated downregulation of TGF-beta1 \u2014 the angiogenic effect was fully reversed by exogenous TGF-beta1 supplementation, confirming target specificity.<\/p>\n For PAD therapy, exosomes offer several advantages over living cell products: they are shelf-stable, do not require cold-chain viability preservation, are non-proliferative (no tumorigenicity concern), and can be manufactured under defined conditions from a master cell bank. The miR-21-5p\/TGF-beta1 axis identified here provides a specific mechanistic target for potency assay development \u2014 a critical need for regulatory submission of any exosome-based vascular product.<\/p>\n The clinical pipeline for MSC\/progenitor cell therapy in CLI includes several active or recently completed trials:<\/p>\n Beyond MSC trials, the LEGenD-1 Phase II trial (NCT04267640) of AMG0001 \u2014 intramuscular plasmid HGF gene therapy \u2014 delivered compelling results for CLI wound healing. In 75 patients with neuroischemic ulcers and moderate ischemia (mean toe pressure 46.1 mmHg), HGF gene therapy significantly shortened time to complete ulcer healing compared with placebo (84 vs. 280 days, p = 0.007), with 77.6% healed at 12 months vs. 46.2% for placebo (p = 0.010). This establishes an important benchmark for the next generation of cell-based approaches to the same target population.<\/p>\n A comprehensive narrative review in Tissue Cell<\/em> (Ribeiro M, 2026) synthesized the clinical evidence across all major cell platforms for PAD and CLI \u2014 bone marrow MSCs, adipose MSCs, umbilical cord cells, fetal progenitor cells, and iPSC-derived products. The review’s main conclusions for practitioners:<\/p>\n The review identifies three innovations most likely to catalyze the next clinical advances: biomaterial-assisted delivery (hydrogels that improve cell retention in ischemic muscle beyond 48 hours), exosome-based products that eliminate cold-chain and viability barriers, and precision patient stratification biomarkers that identify responders vs. non-responders before treatment.<\/p>\n Five distinct therapeutic modalities are now generating clinical and mechanistic data in PAD\/CLI:<\/p>\n The central question has shifted from “do MSCs work in PAD?” to “which formulation, at what dose, in which patients, and at what stage of disease?” \u2014 an inflection point that signals maturation from proof-of-concept to clinical optimization. For the 40% of CLI patients who cannot undergo conventional revascularization, the convergence of gene editing, iPSC manufacturing, and exosome-based therapies is closing the translational gap faster than any single conventional drug development pathway.<\/p>\nhiPSC-Derived MSCs Overcome the Autologous Quality Problem in Diabetic CLI<\/h2>\n
Combining Two Complementary Cell Populations for Vascular Integration<\/h2>\n
Exosomal miR-21-5p: A Defined Therapeutic for Therapeutic Angiogenesis<\/h2>\n
Clinical Landscape: Phase II and Phase IV Trials for PAD\/CLI<\/h2>\n
\n
Systematic Review: 2026 Clinical Evidence Synthesis<\/h2>\n
\n
Where Cell Therapy for PAD Stands at Mid-2026<\/h2>\n
\n
\u0438\u0441\u043f\u043e\u043b\u044c\u0437\u043e\u0432\u0430\u043d\u043d\u0430\u044f \u043b\u0438\u0442\u0435\u0440\u0430\u0442\u0443\u0440\u0430<\/h2>\n
\n